Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001193125-21-069725
Filing Date
2021-03-04
Accepted
2021-03-04 17:16:58
Documents
2
Period of Report
2020-05-28
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A d620489d8ka.htm 8-K/A 20576
2 EX-99.1 d620489dex991.htm EX-99.1 139200
  Complete submission text file 0001193125-21-069725.txt   161014
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

EIN.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-36510 | Film No.: 21715279
SIC: 2834 Pharmaceutical Preparations